ACLY and autoimmune polyendocrinopathy: A real-world study of 22 APS patients who received either standard (≥1000 mg overall) or low (<1000 mg overall) dose rituximab showed that after a 6-month follow up, 19 patients achieved varying degrees of remission, with significant decreases in anticardiolipin antibody (aCL) titer and erythrocyte sedimentation rate level (58).